Tamiflu, the Swiss curative company Roche, and Relenza, Glaxo Smith Kline signature, are the drug that the World Health Organization (WHO) recommends to treat a probable infection with the dreaded H5N1 various of bird influenza that affects humans and whose participation has been rescued already in Turkey and Romania, and is suspected to Greece reached.

Antivirals Tamiflu and Relenza are that in box of infection, “could improve the chances of survival,” says WHO. The complaint is there is sufficient remedy for everyone.

The cave of H5N1

The drugmaker Roche Tamiflu was launched in 1999 to market. Then, the enlarge generated by the drug, that costs in the market from 36 to 44 euros, were not quite spectacular. In the third entertain of this year, sales of Roche rose 17% and the company has ships in the last half year Tamiflu value 377 euros.

Sales of Relenza, Glaxo Smith Kline lab, do not go so well given the remedy is inhaled rsther than than administered in 10 gentle pills such as Tamiflu.

While there is no vaccine opposite bird flu, governments are struggling to take competent supplies of Tamiflu, that the WHO should cover at slightest a entertain of the population, and Roche can not cope with such demand.

As for the private acquisition, Swiss drugmaker warned opposite the squeeze of Tamiflu via the Internet. Yesterday, when those obliged for the portal Ebay private the treatment of the network, given it is a remedy that requires a prescription, Tamiflu reached 3 times its price.

Argentina grown a patent

Not sufficient Tamiflu for everyone, and fighting has damaged out even between member countries of the European Union, that credit each other of carrying paid for too withdrawal others with nothing.

Roche has voiced it will enlarge production of the medicine, though is retiring to lose the patent. Just in box an widespread breaks out the company would be peaceful to accept the sale of generics. For most countries this is too most to expect, and Argentina have already voiced they will develop and market a copy of the drug.

Cipla India’s lab is additionally working on a generic, Roche pronounced he was in negotiations with other Asian country whose name he did not wish to publicize. Several countries and Glaxo Smith Kline investigated opposite time to find a vaccine opposite the virus. The war opposite bird influenza drug has begun.